Literature DB >> 6555215

Modulation of the biologic activities of IgE-binding factor. IV. Identification of glycosylation-enhancing factor as a kallikrein-like enzyme.

M Iwata, J J Munoz, K Ishizaka.   

Abstract

Stimulation of normal rat splenic T cells with pertussigen (lymphocytosis-promoting factor, LPF, from Bordetella pertussis) resulted in the release of a soluble factor that enhanced the glycosylation of IgE-binding factors during their biosynthesis. The soluble factor was detected by the ability of a culture filtrate of LPF-stimulated spleen cells to switch a T cell hybridoma, 23A4, from the formation of unglycosylated IgE-binding factor to the formation of glycosylated IgE-binding factor. The glycosylation-enhancing factor (GEF) had affinity for D-galactose, and the binding of the factor to hybridoma cells via a cell surface galactose was essential for modulation of IgE-binding factors. The GEF was inactivated by irreversible inhibitors of serine proteases such as phenylmethylsulfonyl fluoride, diisopropylfluorophosphate, and p-nitrophenyl ethylpentylphosphonate but was not affected by nonphosphorylating analogues of the organophosphorus compounds. Benzamidine, a competitive and reversible inhibitor of trypsin, also inhibited the glycosylation of IgE-binding factors by GEF. The factor could be purified by absorption to p-aminobenzamidine agarose followed by elution with benzamidine. The capacity of GEF to enhance the glycosylation of IgE-binding factors was inhibited by synthetic substrates of trypsin but not by substrates of chymotrypsin, indicating that GEF is a trypsin-like enzyme. Indeed, trypsin, plasmin, and kallikrein enhanced the glycosylation of IgE-binding factors during their biosynthesis. An inhibitor of trypsin-like enzyme(s), N-alpha-p-tosyl-L-lysine chloromethylketone (TLCK), inhibited trypsin and plasmin but not kallikrein, and TLCK failed to inhibit the GEF-mediated enhancement of glycosylation. It was also found that bradykinin, the biologically active product of cleavage of kininogen by kallikrein, enhanced the glycosylation of IgE-binding factors. The results indicate that GEF is a kallikrein-like enzyme.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6555215

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Low affinity IgE receptors (Fc epsilon RII).

Authors:  D H Conrad
Journal:  Clin Rev Allergy       Date:  1989

2.  A low molecular weight proteinase inhibitor produced by T lymphocytes.

Authors:  D Ganea; M Teodorescu; S Dray
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

Review 3.  Molecular biology of tissue kallikrein.

Authors:  R J MacDonald; H S Margolius; E G Erdös
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

4.  Inactivation of human interleukin-2 (IL-2) by alpha 2-macroglobulin-trypsin complexes.

Authors:  W Borth; M Teodorescu
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

5.  Rat mast cell protease-I enhances immunoglobulin E production by mouse B cells stimulated with interleukin-4.

Authors:  T Yoshikawa; T Imada; H Nakakubo; N Nakamura; K Naito
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

Review 6.  The role of lymphokines in delayed-type hypersensitivity reactions.

Authors:  C L Geczy
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Proteinase-like activity in the cytotoxic factor produced by T cells during dengue virus infection.

Authors:  M Khanna; U C Chaturvedi; B R Srinivasa; K R Swaminathan; A Mathur
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

8.  In vitro modulation of antigen-primed T cells by a glycosylation-inhibiting factor that regulates the formation of antigen-specific suppressive factors.

Authors:  M Iwata; K Ishizaka
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.